Clinical Trial Update: A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes a Phase 1/2 study of AK129, an anti-PD-1 and LAG-3 bispecific antibody, combined with chemotherapy with or without Cadonilimab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK129 (anti-PD-1 and LAG-3 bispecific antibody)
• Cadonilimab

Snippet

Sponsor: Akeso | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING